JS Genetics receives accreditation from College of American Pathology
18/05/10 10:03
Northfield IL—May 18, 2010. JS Genetics Inc. Labs in New Haven CT have
been awarded accreditation by the Accreditation Committee of the American
College of Pathology (CAP) based on the result of a recent site inspection. The
laboratoryʼs director, Dr. Henry Rinder MD, was advised of this national
recognition and congratulated for the excellence of the services being offered.
JS Geneticsʼ laboratory is now one 7000 labs CAP-accredited labs worldwide
About CAP:
The federal government as being equal to or more stringent than the
governmentʼs inspection program recognizes the CAP Laboratory Accreditation
Program, begun in the early 1960s. During the CAP accreditation process, inspectors examine the laboratoryʼs records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications as well as the laboratory equipment, facilities, safety program and record, in addition to the overall
management of the laboratory. This stringent inspection program is designed to
specifically ensure the highest standard of care for laboratory patients.
About JS Genetics:
JS Genetics Inc develops and markets proprietary, low cost, high value DNA
diagnostic tests for underserved medical conditions in newborns, children, and
adolescents. This focus grew out of the recognition that most genetic tests
require blood samples, have longer turn-around times, and are expensive. The
Company's principle strategy is to internally develop tests using cheek swabs for
sample collection and a PCR based testing platform to bring to market accurate,
convenient and cost effective DNA screening tests for adolescents focused in
three key areas of developmental disorders:
been awarded accreditation by the Accreditation Committee of the American
College of Pathology (CAP) based on the result of a recent site inspection. The
laboratoryʼs director, Dr. Henry Rinder MD, was advised of this national
recognition and congratulated for the excellence of the services being offered.
JS Geneticsʼ laboratory is now one 7000 labs CAP-accredited labs worldwide
About CAP:
The federal government as being equal to or more stringent than the
governmentʼs inspection program recognizes the CAP Laboratory Accreditation
Program, begun in the early 1960s. During the CAP accreditation process, inspectors examine the laboratoryʼs records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications as well as the laboratory equipment, facilities, safety program and record, in addition to the overall
management of the laboratory. This stringent inspection program is designed to
specifically ensure the highest standard of care for laboratory patients.
About JS Genetics:
JS Genetics Inc develops and markets proprietary, low cost, high value DNA
diagnostic tests for underserved medical conditions in newborns, children, and
adolescents. This focus grew out of the recognition that most genetic tests
require blood samples, have longer turn-around times, and are expensive. The
Company's principle strategy is to internally develop tests using cheek swabs for
sample collection and a PCR based testing platform to bring to market accurate,
convenient and cost effective DNA screening tests for adolescents focused in
three key areas of developmental disorders:
- Physical Developmental Disorders: Turner Syndrome, Klinefelter Syndrome, & Down's Syndrome
JS Genetics presents to Yale & CURE BioHaven Entrepreneurship Series
05/05/10 09:58
New Haven CT—May 5, 2010.
Alidad Mireskandari, President & CEO of JS Genetics presented at Yale & CURE
BioHaven Entrepreneurship series.
About JS Genetics:
JS Genetics Inc develops and markets proprietary, low cost, high value DNA
diagnostic tests for underserved medical conditions in newborns, children, and
adolescents. This focus grew out of the recognition that most genetic tests
require blood samples, have longer turn-around times, and are expensive. The
Company's principle strategy is to internally develop tests using cheek swabs for
sample collection and a PCR based testing platform to bring to market accurate,
convenient and cost effective DNA screening tests for adolescents focused in
three key areas of developmental disorders:
About CURE:
CURE is the educational and business support network organization for
bioscience in Connecticut, with over 100 members. Its mission is to build
networks and critical mass for the industry within the state, to keep Connecticut
competitive in bioscience, and to tell the Connecticut bioscience story.
an attractive location for new bioscience investment.
facts, figures, and trends.
Alidad Mireskandari, President & CEO of JS Genetics presented at Yale & CURE
BioHaven Entrepreneurship series.
About JS Genetics:
JS Genetics Inc develops and markets proprietary, low cost, high value DNA
diagnostic tests for underserved medical conditions in newborns, children, and
adolescents. This focus grew out of the recognition that most genetic tests
require blood samples, have longer turn-around times, and are expensive. The
Company's principle strategy is to internally develop tests using cheek swabs for
sample collection and a PCR based testing platform to bring to market accurate,
convenient and cost effective DNA screening tests for adolescents focused in
three key areas of developmental disorders:
- Physical Developmental Disorders: Turner Syndrome, Klinefelter Syndrome, & Down's Syndrome
About CURE:
CURE is the educational and business support network organization for
bioscience in Connecticut, with over 100 members. Its mission is to build
networks and critical mass for the industry within the state, to keep Connecticut
competitive in bioscience, and to tell the Connecticut bioscience story.
- CURE's membership includes major pharmaceutical companies, emerging
- CURE works closely with lawmakers, policy makers, and government
an attractive location for new bioscience investment.
- Through its annual economic report and award-winning BioBus program,
facts, figures, and trends.